Key result
Usp28 inactivation reduces MASH severity and hepatocellular carcinoma in diet-induced mouse models.
Why the study?
The pathogenesis of MASH remains poorly understood and effective treatments are limited, highlighting the need for new therapeutic strategies.
Population
MAFLD/MASH patients and two diet-induced mouse models of MASH
Comparison
Genetic or pharmacological inactivation of Usp28 vs control
Design
Preclinical animal and translational study
Authors
Loading...
May support PPARγ targeting in MASH; leaves open clinical relevance pending higher-level evidence.
Inhibition of the deubiquitinase USP28 reduces MASH severity and prevents hepatocellular carcinoma in mouse models by downregulating PPARγ.
Cai et al. (2025) studied Metabolic dysfunction-associated steatohepatitis (MASH). Genetic and pharmacological inactivation of Usp28 was evaluated on MASH severity and hepatocellular carcinoma. Genetic and pharmacological inactivation of Usp28 significantly reduced MASH severity and hepatocellular carcinoma in diet-induced mouse models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: